Advances in Potential M-protein Peptide-based Vaccines for Preventing Rheumatic Fever and Rheumatic Heart Disease

Overview

Journal Immunol Res

Specialty Allergy & Immunology

Date 2006 Dec 19

PMID 17172649

Citations 7

Authors

Michael R Batzloff

Manisha Pandey

Colleen Olive

Michael F Good

Affiliations

Soon will be listed here.

Abstract

Rheumatic fever (RF) and rheumatic heart disease (RHD) are postinfectious complications of an infection (or repeated infection) with the Gram-positive bacterium, Streptococcus pyogenes (also known as group A streptococcus, GAS). RF and RHD are global problems and affect many indigenous populations of developed countries and many developing countries. However, RF and RHD are only part of a larger spectrum of diseases caused by this organism. The development of a vaccine against GAS has primarily targeted the abundant cell-surface protein called the M-protein. This review focuses on different M-protein-based-subunit vaccine approaches and the different delivery technologies used to administer these vaccine candidates in preclinical studies.

Citing Articles

Rheumatic heart disease knowledge and associated factors among nurses working in cardiac centers at public and private hospitals of Addis Ababa: cross sectional study.

Techane T, Legesse B, Ayalew Y, Hailu A BMC Nurs. 2022; 21(1):130.

PMID: 35619104 PMC: 9137194. DOI: 10.1186/s12912-022-00910-5.

Recent progress in adjuvant discovery for peptide-based subunit vaccines.

Azmi F, Ahmad Fuaad A, Skwarczynski M, Toth I Hum Vaccin Immunother. 2013; 10(3):778-96.

PMID: 24300669 PMC: 4130256. DOI: 10.4161/hv.27332.

Defense from the Group A Streptococcus by active and passive vaccination with the streptococcal hemoprotein receptor.

Huang Y, Fisher M, Nasrawi Z, Eichenbaum Z J Infect Dis. 2011; 203(11):1595-601.

PMID: 21592989 PMC: 3096790. DOI: 10.1093/infdis/jir149.

Factors associated with Group A Streptococcus emm type diversification in a large urban setting in Brazil: a cross-sectional study.

Tartof S, Reis J, Andrade A, Ramos R, Reis M, Riley L BMC Infect Dis. 2010; 10:327.

PMID: 21070669 PMC: 2994873. DOI: 10.1186/1471-2334-10-327.

Antibodies against a surface protein of Streptococcus pyogenes promote a pathological inflammatory response.

Kahn F, Morgelin M, Shannon O, Norrby-Teglund A, Herwald H, Olin A PLoS Pathog. 2008; 4(9):e1000149.

PMID: 18787689 PMC: 2522270. DOI: 10.1371/journal.ppat.1000149.

References

Re F, Strominger J . Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem. 2001; 276(40):37692-9. DOI: 10.1074/jbc.M105927200. View

Brandt E, Sriprakash K, Hobb R, Hayman W, Zeng W, Batzloff M . New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nat Med. 2000; 6(4):455-9. DOI: 10.1038/74719. View

Mannam P, Jones K, Geller B . Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Infect Immun. 2004; 72(6):3444-50. PMC: 415684. DOI: 10.1128/IAI.72.6.3444-3450.2004. View

Ferretti J, McShan W, Ajdic D, Savic D, Savic G, Lyon K . Complete genome sequence of an M1 strain of Streptococcus pyogenes. Proc Natl Acad Sci U S A. 2001; 98(8):4658-63. PMC: 31890. DOI: 10.1073/pnas.071559398. View

Olive C, Batzloff M, Horvath A, Wong A, Clair T, Yarwood P . A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies. Infect Immun. 2002; 70(5):2734-8. PMC: 127950. DOI: 10.1128/IAI.70.5.2734-2738.2002. View

Bessen D, Fischetti V . Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci. Infect Immun. 1988; 56(10):2666-72. PMC: 259627. DOI: 10.1128/iai.56.10.2666-2672.1988. View

LYAMPERT I, Danilova T, Borodyuk N, Beletskaya L . Mechanism of formation of antibodies to heart tissue in immunization with group A streptococci. Folia Biol (Praha). 1966; 12(2):108-15. View

Kotloff K, Corretti M, Palmer K, Campbell J, Reddish M, Hu M . Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. JAMA. 2004; 292(6):709-15. DOI: 10.1001/jama.292.6.709. View

MASSELL B, Honikman L, AMEZCUA J . Rheumatic fever following streptococcal vaccination. Report of three cases. JAMA. 1969; 207(6):1115-9. View

10.

Carapetis J, Steer A, Mulholland E, Weber M . The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005; 5(11):685-94. DOI: 10.1016/S1473-3099(05)70267-X. View

11.

Seifert R, Schultz G, Metzger J, Wiesmuller K, Jung G, Bessler W . Activation of superoxide formation and lysozyme release in human neutrophils by the synthetic lipopeptide Pam3Cys-Ser-(Lys)4. Involvement of guanine-nucleotide-binding proteins and synergism with chemotactic peptides. Biochem J. 1990; 267(3):795-802. PMC: 1131368. DOI: 10.1042/bj2670795. View

12.

Takeda K, Kaisho T, Akira S . Toll-like receptors. Annu Rev Immunol. 2003; 21:335-76. DOI: 10.1146/annurev.immunol.21.120601.141126. View

13.

Jackson D, Lau Y, Le T, Suhrbier A, Deliyannis G, Cheers C . A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A. 2004; 101(43):15440-5. PMC: 523460. DOI: 10.1073/pnas.0406740101. View

14.

Tam J . Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci U S A. 1988; 85(15):5409-13. PMC: 281766. DOI: 10.1073/pnas.85.15.5409. View

15.

Olive C, Toth I, Jackson D . Technological advances in antigen delivery and synthetic peptide vaccine developmental strategies. Mini Rev Med Chem. 2002; 1(4):429-38. DOI: 10.2174/1389557013406666. View

16.

Komaroff A, Pass T, Aronson M, Ervin C, Cretin S, Winickoff R . The prediction of streptococcal pharyngitis in adults. J Gen Intern Med. 1986; 1(1):1-7. DOI: 10.1007/BF02596317. View

17.

Zabriskie J, Poon-King T, Blake M, Michon F, Yoshinaga M . Phagocytic, serological, and protective properties of streptococcal group A carbohydrate antibodies. Adv Exp Med Biol. 1997; 418:917-9. DOI: 10.1007/978-1-4899-1825-3_214. View

18.

DAlessandri R, Plotkin G, Kluge R, WITTNER M, FOX E, DORFMAN A . Protective studies with group A streptococcal M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization with Type 3 or Type 12 group A Streptococcus. J Infect Dis. 1978; 138(6):712-8. DOI: 10.1093/infdis/138.6.712. View

19.

Pruksakorn S, Galbraith A, Houghten R, Good M . Conserved T and B cell epitopes on the M protein of group A streptococci. Induction of bactericidal antibodies. J Immunol. 1992; 149(8):2729-35. View

20.

Norgard M, Arndt L, Akins D, Curetty L, Harrich D, Radolf J . Activation of human monocytic cells by Treponema pallidum and Borrelia burgdorferi lipoproteins and synthetic lipopeptides proceeds via a pathway distinct from that of lipopolysaccharide but involves the transcriptional activator NF-kappa B. Infect Immun. 1996; 64(9):3845-52. PMC: 174301. DOI: 10.1128/iai.64.9.3845-3852.1996. View